Erratum: Allopurinol, rutin, and quercetin attenuateh yperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement (Am J Physiol Renal Physiol (2009) 297 (F1080–F1091) DOI: 10.1152/ajprenal.90767.2008);Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: Renal organic ion transporter involvement

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 4, 2009, Pages F558-

  Hu, Qing Hua ^a   Wang, Chuang ^a   Li, Jian Mei ^a   Zhang, Dong Mei ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

High uric acid; Hypouricemic agents; rSLC22A; rSLC2A9; rUAT

Indexed keywords

ALLOPURINOL; ANION; CATION; CREATININE; FRUCTOSE; MEMBRANE PROTEIN; NITRIC OXIDE; PRIMER DNA; PROSTAGLANDIN E2; PROTEIN ROAT1; PROTEIN ROCT1; PROTEIN ROCT2; PROTEIN RRST; PROTEIN RSLC2A9V2; PROTEIN RUAT; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; EXCRETION; FLUID INTAKE; FOOD INTAKE; HYPERURICEMIA; ION TRANSPORT; KIDNEY DISEASE; MALE; METABOLIC SYNDROME X; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAMETER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SUGAR INTAKE; UPREGULATION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 70349647191     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90767.2008_COR     Document Type: Erratum

References (75)

1. Abramson RG, Lipkowitz MS. Carrier-mediated concentrative urate transport in rat renal membrane vesicles. Am J Physiol Renal Fluid Electrolyte Physiol 248: F574-F584, 1985. (Pubitemid 15056873)
2. Abramson RG, King VF, Reif MC, Leal-Pinto E, Baruch SB. Urate uptake in membrane vesicles of rat renal cortex: effect of copper. Am J Physiol Renal Fluid Electrolyte Physiol 242: F158-F170, 1982. (Pubitemid 12047833)
3. Ahmad NS, Farman M, Najmi MH, Mian KB, Hasan A. Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout. J Ethnopharmacol 117: 478-482, 2008.
4. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 279:16229-16236, 2004. (Pubitemid 38509316)
5. Bannasch D, Safra N, Young A, Karmi N, Schaible RS, Ling GV. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet 4: e1000246, 2008.
6. Bayrak O, Uz E, Bayrak R, Turgut F, Atmaca AF, Sahin S, Yildirim ME, Kaya A, Cimentepe E, Akcay A. Curcumin protects against ischemia/reperfusion injury in rat kidneys. World J Urol 26: 285-291, 2008. (Pubitemid 351957593)
7. Bouriche H, Miles EA, Selloum L, Calder PC. Effect of Cleome arabica leaf extract, rutin and quercetin on soybean lipoxygenase activity and on generation of inflammatory eicosanoids by human neutrophils. Prostaglandins Leukot Essent Fatty Acids 72: 195-201, 2005. (Pubitemid 40139084)
8. Carroll JJ, Coburn H, Douglass R, Babson AL. A simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem 17: 158-160, 1971.
9. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56: 570-580, 1999. (Pubitemid 29406884)
10. Collantes Estevez E, Pineda Priego M, Añon Barbudo J, Sanchez Guijo P. Hyperuricemia-hyperlipemia association in the absence of obesity and alcohol abuse. Clin Rheumatol 9: 28-31, 1990.
11. Cunha TS, Farah V, Paulini J, Pazzine M, Elased KM, Marcondes FK, Cláudia Irigoyen M, De Angelis K, Mirkin LD, Morris M. Relationship between renal and cardiovascular changes in a murine model of glucose intolerance. Regul Pept 139: 1-4, 2007. (Pubitemid 46216490)
12. Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology (Oxford) 48: 222-226, 2009.
13. Döring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Völzke H, Illig T, Meitinger T, Wichmann HE, Meisinger C. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40: 430-436, 2008.
14. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, Barshop BA, Nigam SK. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33: 180-192, 2008. (Pubitemid 351629526)
15. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266: 3008-3011, 1991.
16. Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C, Sautin YY, Johnson RJ, Nakagawa T. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 293: F1256-F1261, 2007. (Pubitemid 47583960)
17. Grover B, Buckley D, Buckley AR, Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 308: 949-956, 2004. (Pubitemid 38263970)
18. Gutiérrez-Venegas G, Jiménez-Estrada M, Maldonado S. The effect of flavonoids on transduction mechanisms in lipopolysaccharide-treated human gingival fibroblasts. Int Immunopharmacol 7: 1199-1210, 2007. (Pubitemid 47049702)
19. Habu Y, Yano I, Okuda M, Fukatsu A, Inui K. Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. Biochem Pharmacol 69: 993-999, 2005. (Pubitemid 40312716)
20. Habu Y, Yano I, Takeuchi A, Saito H, Okuda M, Fukatsu A, Inui K. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem Pharmacol 66: 1107-1114, 2003. (Pubitemid 37083607)
21. Haidari F, Rashidi MR, Eshraghian MR, Mahboob SA, Shahi MM, Keshavarz SA. Hypouricemic and antioxidant activities of Allium cepa Lilliaceae and quercetin in normal and hyperuricemic rats. Saudi Med J 29: 1573-1579, 2008.
22. Harlfinger S, Fork C, Lazar A, Schömig E, Gründemann D. Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol 372: 125-130, 2005. (Pubitemid 41504159)
23. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology 20: 125-133, 2005.
24. Heemskerk S, Wouterse AC, Russel FG, Masereeuw R. Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia. Eur J Pharmacol 584: 390-397, 2008.
25. Hong SS, Seo K, Lim SC, Han HK. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol Res 56: 468-473, 2007. (Pubitemid 350137768)
26. Hosoyamada M, Ichida K, Enomoto A, Hosoya T, Endou H. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15: 261-268, 2004. (Pubitemid 38140766)
27. Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol Renal Physiol 276: F122-F128, 1999. (Pubitemid 29061732)
28. Hu E, Chen Z, Fredrickson TA, Spurr N, Gentle S, Sims M, Zhu Y, Halsey W, Van Horn S, Mao J, Sathe GM, Brooks DP. Rapid isolation of tissue-specific genes from rat kidney. Exp Nephrol 9: 156-164, 2001. (Pubitemid 32041494)
29. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, Endou H. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63: 143-155, 2003. (Pubitemid 35463915)
30. Kamalakkannan N, Stanely Mainzen Prince P. The influence of rutin on the extracellular matrix in streptozotocin-induced diabetic rat kidney. J Pharm Pharmacol 58: 1091-1098, 2006. (Pubitemid 44213642)
31. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002. (Pubitemid 35386908)
32. Knorr BA, Lipkowitz MS, Potter BJ, Masur SK, Abramson RG. Isolation and immunolocalization of a rat renal cortical membrane urate transporter. J Biol Chem 269: 6759-6764, 1994.
33. Le MT, Shafiu M, Mu W, Johnson RJ. SLC2A9-a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 23: 2746-2749, 2008.
34. Leal-Pinto E, Cohen BE, Lipkowitz MS, Abramson RG. Functional analysis and molecular model of the human urate transporter/channel, hUAT. Am J Physiol Renal Physiol 283: F150-F163, 2002. (Pubitemid 34680482)
35. Li JM, Che CT, Cheng CHK. Desoxyrhaponticin inhibits glucose uptake in the intestine and kidney: a potential agent in the control of postprandial hyperglycemia. J Pharmacol Exp Ther 320: 38-46, 2007.
36. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J 19: 491-498, 2004. (Pubitemid 38316522)
37. Lu R, Chan BS, Schuster VL. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol Renal Physiol 276: F295-F303, 1999. (Pubitemid 29102295)
38. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999. (Pubitemid 29418240)
39. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T, Morimoto Y, Kamakura K, Sakurai Y, Nonoyama S, Kanai Y, Shinomiya N. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83: 744-751, 2008.
40. Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H. Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion- induced acute kidney injury. Drug Metab Dispos 36: 649-654, 2008.
41. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71: 900-905, 2001. (Pubitemid 32417351)
42. McArdle PF, Parsa A, Chang YP, Weir MR, O'Connell JR, Mitchell BD, Shuldiner AR. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order Amish. Arthritis Rheum 58: 2874-2881, 2008.
43. Miatello R, Vázquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 18: 864-870, 2005. (Pubitemid 40745275)
44. Mo SF, Zhou F, Lv YZ, Hu QH, Zhang DM, Kong LD. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol Pharm Bull 30:1551-1556, 2007. (Pubitemid 47282199)
45. Moore PK, Griffiths RJ, Lofts FJ. The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1. Biochem Pharmacol 32: 2813-2817, 1983.
46. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9: 746-752, 1996. (Pubitemid 26271219)
47. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290: F625-F631, 2006. (Pubitemid 43724964)
48. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructoseinduced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 1: 80-86, 2005.
49. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez- Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2-7, 2003. (Pubitemid 35316757)
50. Nigam SK, Bush KT, Bhatnagar V. Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephrol 3: 443-448, 2007. (Pubitemid 47123587)
51. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci 25:263-271, 2005. (Pubitemid 40725056)
52. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 47: 610-613, 2002. (Pubitemid 35461313)
53. Reid G, Wolff NA, Dautzenberg FM, Burckhardt G. Cloning of a human renal p-aminohippurate transporter, hROAT1. Kidney Blood Press Res 21: 233-237, 1998. (Pubitemid 28438636)
54. Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, Johnson RJ, Nakagawa T. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 18: 2724-2731, 2007. (Pubitemid 47531199)
55. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 26: 59-62, 2008.
56. Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 16: 2081-2087, 2008.
57. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24: 450-470, 2007. (Pubitemid 46295167)
58. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep 3: 197-202, 2007.
59. Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol Endocrinol Metab 268: E1-E5, 1995.
60. Sakurai Y, Motohashi H, Ueo H, Masuda S, Saito H, Okuda M, Mori N, Matsuura M, Doi T, Fukatsu A, Ogawa O, Inui K. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res 21: 61-67, 2004. (Pubitemid 38122293)
61. Sánchez-Lozada LG, Tapia E, Bautista-García P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294: F710-F718, 2008.
62. Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 292: F423-F429, 2007. (Pubitemid 46105280)
63. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237-247, 2005. (Pubitemid 40019245)
64. Sauvant C, Holzinger H, Gekle M. Prostaglandin E2 inhibits its own renal transport by downregulation of organic anion transporters rOAT1 and rOAT3. J Am Soc Nephrol 17: 46-53, 2006.
65. Sauvant C, Hesse D, Holzinger H, Evans KK, Dantzler WH, Gekle M. Action of EGF and PGE2 on basolateral organic anion uptake in rabbit proximal renal tubules and hOAT1 expressed in human kidney epithelial cells. Am J Physiol Renal Physiol 286: F774-F783, 2004. (Pubitemid 38365097)
66. Singh D, Chander V, Chopra K. The effect of quercetin, a bioflavonoid on ischemia/reperfusion induced renal injury in rats. Arch Med Res 35: 484-494, 2004. (Pubitemid 41043618)
67. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51-59, 2006.
68. Stanely Mainzen Prince P, Karthick M. Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol 21: 1-6, 2007. (Pubitemid 46555353)
69. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism 57: 845-852, 2008. (Pubitemid 351697915)
70. Tay A, Ozçelikay AT, Altan VM. Effects of L-arginine on blood pressure and metabolic changes in fructose-hypertensive rats. Am J Hypertens 15: 72-77, 2001.
71. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107: 217-224, 2001. (Pubitemid 32096838)
72. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40: 437-442, 2008.
73. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 54: 9798-9804, 2006. (Pubitemid 46158973)
74. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51: 913-921, 1997. (Pubitemid 27249124)
75. Zhu JX, Wang Y, Kong LD, Yang C, Zhang X. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol 93: 133-140, 2004. (Pubitemid 38739283)